Several drugs used in MM therapy, such as melphalan, even at low doses, can induce DDR activation [28, 29]; in this context, we have recently contributed to delineating a link between the activation of DDR induced by chemotherapeutics and the transcriptional regulation of NKG2D and DNAM-1 ligands in MM. The gene discussed is CD226; the disease is Miyoshi myopathy.